Pharmascience Inc. Launches Royalmount Laboratories, a New Analytical Service Division in Montreal

Published: May 13, 2019

Pharmascience Inc. has launched its new division in Montreal, Royalmount Laboratories. Royalmount Laboratories specializes in contract research services for both local and international companies. This new division leverages Pharmascience’s strength in bioanalytical operations with a new competency in Cannabis testing for third parties.

“Pharmascience has been testing pharmaceutical products for over 35 years and doing its own bioanalysis on clinical trials for over 25 years,” said David Goodman, Chief Executive Officer at Pharmascience Inc. “Offering our expertise and regulatory knowledge in analytical and bioanalytical testing to now help clients obtain cannabis testing is a bold new business expansion driven by our continued internal drive to be at the technical foreground of new markets.”

In March 2019, Pharmascience’s licence to test cannabis was transitioned to the new Cannabis Regulations. Fully equipped with state-of-the-art equipment supplied by Shimadzu Corporation, the cannabis testing laboratory has the capability and capacity to perform all Health Canada required tests, including the full spectrum of pesticides in both dried flower and oil products with Pharmascience’s usual turnaround times.

“Our existing bioanalytical business has expanded significantly this past year,” added Adrien Musuku, Royalmount Laboratories Director of Operations, “We completed a Food and Drug Administration audit confirming that our procedures meet FDA regulatory requirements in 2018. We are very excited to add cannabis testing to complement our existing bioanalytical operation. We hope to become Quebec’s premier testing laboratory in the very near future.” The bioanalytical operation is currently working with external clients for the biological drug quantification in preclinical and clinical studies.